News & AnalysisElevian nabs $40m Series AElevian, an emerging biotech company, has raised $40 million in Series A funding.ByIris Dorbian17 September 2021•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs